LLY Up 20% YTD: Is the Obesity Drug Trade Still Early?

$LLY is up 4% pre-market and 20% year-to-date, and before you say "I missed it," consider this: only 3% of eligible patients globally and 10% in the US currently have access to obesity care. That's not a trade that's over. That's a trade that's barely started its first cup of coffee.

Eli Lilly raised its full-year revenue forecast for the third time this year, now projecting $91 to $92 billion, driven by surging demand for Zepbound and Mounjaro. The company's CEO Dave Ricks went on CNBC and described the room for expansion as "dramatic," which, as understatements go, is doing a lot of heavy lifting. Lilly is also pushing into women's health and psychedelics, which sounds like a very aggressive company retreat agenda but is actually a smart pivot to extend moat beyond the current GLP-1 cycle.

The macro kicker here is policy: a Medicare GLP-1 bridge program, developed alongside the Trump administration, now lets seniors access Zepbound and Mounjaro for $50 per month out of pocket starting July 1st. That is a distribution unlock that Wall Street is still underpricing. Broader access plus untapped global population plus a pipeline expanding into new therapeutic areas equals a compounding story, not a one-hit wonder.

Meanwhile, $MRK is quietly doing its own thing. Merck gained 2% after raising its full-year profit forecast, powered by blockbuster cancer drug Keytruda and a new subcutaneous version, Keytruda QLEX. It's the quieter pharma win of the week, the kind that doesn't trend on fintwit but that long-only funds are absolutely loading up on. European market restrictions are a real headwind worth watching, but the core Keytruda franchise remains a cash machine.

Zoom out and the broader market context actually supports this rotation. The VIX has dropped from 19.45 to 17.52 over the past week, the S&P 500 is grinding back toward 7,743, and 10-year Treasury yields are sitting just under the 5% psychological line. When fear falls and rates stabilize, quality growth with real earnings tends to attract capital. Healthcare checks that box right now in a way that volatile AI infrastructure names simply do not.

The pharma trade is the boring trade everyone ignores until it's up 35%, at which point everyone asks why they didn't see it coming. Well. Here it is. You're seeing it.